- Home
- KROS vs ALEC Comparison
KROS vs ALEC Comparison
Compare KROS & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | ALEC |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 194.3M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KROS | ALEC |
|---|---|---|
| Price | $11.26 | $2.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $21.86 | $4.83 |
| AVG Volume (30 Days) | 277.5K | ★ 886.4K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $2,751.79 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.69 | $1.09 |
| 52 Week High | $22.55 | $3.40 |
Technical Indicators
Market Signals| Indicator | KROS | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 57.90 |
| Support Level | $10.64 | $1.93 |
| Resistance Level | $11.55 | $2.05 |
| Average True Range (ATR) | 0.50 | 0.16 |
| MACD | 0.10 | 0.06 |
| Stochastic Oscillator | 85.91 | 83.67 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.